Familial Mediterranean fever is an autosomal recessive disorder characterized by mutations in the MEFV gene which encodes pyrin. Most of the mutations occur on exon 10, with the most common being M694V. Pyrin is a 781-aa protein that works to interact with apoptosis-associated speck-like protein which contains a caspase recruitment domain (ASC) to modulate IL-1β processing and inhibit NF-κB activation and apoptosis. The effects of mutated pyrin continue to be controversial. It is believed that a mutated pyrin leads to inflammation mediated by IL-1 and continuing leukocytic apoptosis; however, there are studies that contradict this current belief. Colchicine is the accepted treatment for FMF that with daily dosing, can cause remission or reduction of attacks (6) . The mechanism of action of colchicine is controversial, but the protein pyrin is associated with microtubules so perhaps the disruption of microtubules prevents the action of pyrin on the generation of caspase activity.
Muckle-Wells syndrome is part of cryopyrin-associated periodic syndromes. It is an autosomal dominant disorder that presents with febrile episodes lasting 24-48 hours accompanied by abdominal pain, urticaria, arthritis, conjunctivitis, progressive deafness, and development of amyloidosis (7) . It is associated with the NLRP3 gene (also is known as CIAS1) which encodes cryopyrin. This protein is part of the NALP3 inflammasome cascade. This cascade activates IL-1β and IL-18 through caspase 1. The NALP3 inflammasome is also activated by macrophages which increases the inflammation (8, 9) .
Tumor necrosis factor receptor associated periodic syndrome is an autosomal dominant disease. It manifests as fever episodes lasting 1-3 weeks, conjunctivitis, periorbital edema, arthralgia, myalgia, an erythematous migratory plaque, and possible polyserositis. The TN-FRSF1A gene encodes a transmembrane TNF receptor, which is bound by TNF proteins involved with the inflammation process. The exact pathophysiology is unknown (10) . In theory, TRAPS should respond to etanercept since it is effectively replacement therapy; however, in many cases, IL-1 blockade is more efficacious.
Hyperimmunoglobulinemia D with periodic fever syndrome is an autosomal recessive disorder that is associated with the MVK gene. HIDS manifests as fever episodes with arthralgia, gastrointestinal symptoms, rash, and lymphadenopathy. MVK mutation causes underactivity of mevalonate kinase, which leads to increased mevalonic acid (11) . How mevalonic acid affects inflammation and causes a periodic fever is unknown.
Majeed syndrome presents with chronic recurrent multifocal osteomyelitis, inflammatory dermatosis, and congenital dyserythropoietic anemia. It is an autosomal recessive disorder at the LPIN2 gene (3). The lipin-2 protein may be involved with oxidative stress response and mitosis (12) , but it appears to be independent of the inflammasome.
In Mendelian genetics, it is accepted that autosomal dominant syndromes only require one gene abnormality. Autosomal recessive syndromes require two gene mutations on complementary alleles. There have been reports of abnormal genetics with PFS that differ from the current understanding. We performed a retrospective study to examine cases of difficult-to-control PFS and explore the genetics of each case. Phenotypic expression of autonomic recessive syndromes can occur with heterozygous and compound heterozygous mutations We observed four cases of heterozygous mutations in the MEFV gene and one case of a heterozygous mutation in the TRNT1 gene that led to the expression of symptomatic PFS. There were two cases with compound heterozygous mutations in the MEFV gene that resulted in phenotypic expression of FMF.
Methods
In these seven cases, patients presented with symptoms that resembled FMF. There were periodic fevers and joint and abdominal pains. One patient had erysipelas rashes. In the majority of these cases, there was a response to colchicine.
Muckle-Wells syndrome can present with non-classical genetics MWS was diagnosed clinically in two patients. These patients presented with a history of urticaria and periodic fevers. One patient had abdominal pain during episodes, and the other patient had progressive deafness. Patients responded to interleukin-1 receptor antagonists. While these patients have symptoms that resemble MWS, genetic analysis revealed a heterozygous mutation in NOD2 or compound heterozygous mutations in the CIAS1 and MEFV genes. Here, the genetic diagnosis is not consistent with the clinical diagnosis.
NOD mutations have a variety of different phenotypic expressions
We observed different expressions of the NOD gene mutation. It can present as fever of unknown origin. This patient presents with periodic fevers every two to four weeks with gastrointestinal and articular symptoms. These symptoms are responsive to steroids. The NOD gene mutation also presented as severe, refractory Crohn's disease with fistula formation, polyarthralgias, and subcutaneous nodules. The patient failed 6-MP, mesalamine, plaquenil, pentasa, methotrexate, metronidazole and steroids, but is responsive to sulfasalazine and certolizumab pegol.
Novel syndromes involving the TNFRSF-1A gene
We report a novel presentation of TRAPS involving a heterozygous R121Q mutation in the TNFRSF-1A gene. The patient does not have a rash, fevers, abdominal or chest pain, or conjunctivitis. The patient does have musculoskeletal pain secondary to hypermobility, gastric reflex, Raynaud's syndrome, genetic celiac disease, and growth failure.
Novel syndromes involving the LPIN2 gene
Another novel presentation involves a heterozygous mutation of the LPIN2 gene manifesting as adult-onset Still's disease (SoJIA). The patient had a history of episodic fevers as a child with non-pruritic erythematous macular rashes, conjunctivitis, glossitis, night sweats, and arthralgias. These episodes are responsive to prednisone and colchicine. His presentation is most consistent with adult-onset Still's disease rather than Majeed syndrome.
Discussion
PFS are difficult to diagnose given their rarity and pleomorphic presentations. This spectrum of disease is typically diagnosed clinically and often not subjected to genetic testing. Many of these diseases, other than PFAPA and adult-onset Still's disease, are associated with genetic mutations. In our retrospective clinical observations, we observed cases where the treatment based on clinical presentation failed. In over half of the cases, we found that by using the genetic diagnoses to direct treatment plans, the patients responded.
Many of the cases presented with non-classi- There have been reports of compound heterozygous mutations in the literature. Caglayan, et. al looked at the frequency of compound heterozygous mutations at their institution in Turkey and found 66 Turkish patients with compound heterozygous mutations who displayed symptoms typical of FMF. They also found that the most common MEFV mutation was M694V, which was found in 32% of the alleles. Out of 66 patients, 41 had a compound heterozygous mutation involving M694V. The next most common mutations found were E148Q at 20.6%, V726A at 17% and M680I at 14.5%. M694I is a rare mutation and seen 0.7% to 5.3% of the time (14) . Treatment with colchicine was effective in 83% of patients (2).
We observed a case (case 2) of three compound heterozygous mutations. The patient's family is a carrier of three compound heterozygous mutations. The mother is homozygous for E148Q and two other mutations on the same chromosome. She reports chronic joint symptoms, fevers of unknown origin, and an episode of pleurisy in the past alleviated by colchicine. His older brother tested positive for FMF and has symptoms of fever and chest and abdominal pain responsive to colchicine. E148Q was originally believed to be a nonpathologic mutation (15) . However, homozygous mutations display symptoms and require treatment with colchicine (16) . There are also reports of E148Q causing FMF in compound heterozygous mutations. Fukushima et al. reported a case of 3 adult family members of Japanese descent, one mother and her two children, with a compound heterozygosity for L110P/E148Q/M694I. The husband/ father of the family members had no muta-tions. The mother had symptoms of fever and abdominal, chest, and joint pains since 30 years old. The older child had symptoms of fever and joint and abdominal pain 3-4 times a year since she was a child. The younger child had fever and abdominal pain once a month since the age of 30. Colchicine helped in all three cases (4).
We observed a case (case 7) where the genetic mutation did not normally correspond to the clinical diagnosis. There was a patient with FMF that had a heterozygous TRNT1 mutation, which normally manifests as sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). SIFD is an autosomal recessive disease that responds to IVIg, regular blood transfusions, and iron chelation (17) . Not only did the patient respond to IVIg, but also high dose colchicine. This challenges the way we think about linking specific genes to diseases. It suggests that there are more downstream effects and mutations that may not yet be detectable by current genetic testing. Even though certain genetics are seen mostly with specific diseases, there could be other genes or proteins that cause specific symptoms to manifest.
NOD2 mutations have a broad presentation. They are associated with inflammatory diseases such as Crohn's disease and Blau syndrome. In one of our reported cases (case 9), we observed a NOD2 mutation associated with fever of unknown origin, which has not been reported in the literature. Our patient's specific variant could be a benign mutation resulting in a mild presentation of PFS. Other epigenetic changes could have affected the expression of the mutated protein. The patient could also have other genomic mutations that were not detected in the genomic screen that could be affecting the expression of the NOD2 mutation. The NOD2 mutation is also linked to severe presentations of Crohn's disease (18) . We observed another case (case 1) where the patient had failed multiple Crohn's disease therapies. We observed a third case (case 12) where the NOD2 mutation was associated with MWS. These three cases illustrate how different mutations in the NOD2 gene can phenotypically be expressed differently. A substitution of cysteine for threonine was seen with fever of unknown origin. A duplicate cysteine was seen with severe Crohn's disease. A substitution of cysteine for alanine was seen with MWS. These cases suggest that the different mutated proteins that occur with these mutations have drastically different functions in the human body. The correct NOD2 gene expression is likely to be very important in the inflammation cascade.
The CIAS1or NLRP3 gene is associated with MWS (19) . It is inherited in an autosomal dominant pattern. We observed a case (case 11) where the patient presented with two separate heterozygous mutations in the CIAS1 gene and the MEFV gene. These mutations are associated with an abnormal presentation of MWS that includes urticarial and abdominal pain with periodic fevers seen with FMF. Although FMF is an autosomal recessive disorder, this case illustrates how a heterozygous mutation in an autosomal recessive disorder can be co-expressed with an autosomal dominant disorder. Both gene products, cyropyrin from CIAS1 and pyrin from MEFV, are involved with the assembly of the inflammasome, a molecular complex that helps trigger and regulate the inflammatory process. The V200M mutation in CIAS1 gene leading to a gain of function in cryopyrin and the E148Q mutation in MEFV gene leading to a dysfunctional or reduced pyrin could both be contributing to an inappropriately prolonged inflammatory response in the patient, manifesting as recurrent episodes of fever, abdominal pain, urticaria, and joint tenderness. While FMF is an autosomal recessive condition requiring a homozygous mutation, it still does not preclude the possibility that the patient's presentation is a hybrid between MWS and FMF, given that their respective gene mutations may interact in the inflammasome. There has been another case report of a hybrid CIAS1 and MEFV gene mutations (20) . The case reported periodic fevers with intact hearing. Episodes were controlled with IL-1 receptor antagonist, colchicine, and prednisone. In both our case and the previous case report, the hybrid presentation of MWS and FMF was responsive to treatment with an IL-1 receptor antagonist.
LPIN2 gene mutation is believed to be associated with Majeed syndrome; however, we observed a case (case 13) that was more consistent with adult-onset Still's disease. The patient presented with daily fevers, joint pain, and a macular rash, which are symptoms consistent with adult-onset Still's disease (21) . There is currently no known gene to cause adult-onset Still's disease. However, genetic screening showed a mutation in the LPIN2 gene. Majeed syndrome is an autosomal recessive syndrome, and according to Mendelian genetics, Majeed syndrome symptoms should not be expressed. This case suggests that abnormal lipin-2 protein may be involved in an inflammatory cascade that is abnormal in adult-onset Still's disease.
We observed two different presentations of the same mutation in the TNFRSF1A gene at R121Q. TRAPS is an autosomal dominant disease. One patient (case 14) was asymptomatic while the other patient (case 15) had episodes of fevers, chest, abdominal, and joint pains, oral ulcers, and numbness, paresthesias, and weakness in the extremities. These observations raise questions whether there are more genes, proteins, and pathways involved in TRAPS. These two cases have the genetics of TRAPS, and we would expect that the patients present with TRAPS symptoms. However, we see two abnormal presentations of TRAPS despite having the expected genetic mutations.
In our retrospective case studies, we observe multiple examples where the clinical diagnoses do not correspond with the genetic diagnoses. We found that genetic testing was helpful in guiding some treatment plans. In case 7, the patient was phenotypically diagnosed with FMF while genotypically diagnosed with SIFD. The patient's partial response to IVIg may be explained by the genetics.
There were also many examples of non-classical Mendelian genetics, and it challenges the way we think, approach, and provide genetic counseling to families with PFS. We suggest that extensive genetic testing be used in all patients presenting with a PFS other than classic presentations of PFAPA (22, 23) .
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